

November 06, 2019

TAKE/BSE/2019-20
The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai – 400001
Scrip Code: 532890

TAKE/NSE/2019-20
The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai – 400051
Symbol: TAKE

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on Wednesday, November 06, 2019

We wish to inform you that the Board of Directors of the Company, in its meeting held on Wednesday, November 06, 2019, approved/took note of the following:

1. Resignation of Mr. Ganesan Raghuram (DIN: 01099026) from the Directorship of the Company with effect from close of business hours of November 05, 2019. Please refer Annexure I for further information required to be provided in terms of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.s
2. Appointment of Mr. Balasubramanian Srinivasan (Srini Srinivasan) (DIN: 07121117) as an Additional Director (Independent Category) with effect from November 06, 2019. Please refer Annexure II for the brief profile of Mr.Srinivasan and FORM B under SEBI (Prohibition of Insider Trading) Regulations, 2015.
3. Re-appointment of Ms. Uma Ratnam Krishnan (DIN:00370425) as an Independent Director for a further period of five years commencing from November 12, 2019 to November 11, 2024.
4. Unaudited Financial Results of the Company (Standalone) and together with its subsidiaries (Consolidated) for the second quarter and half year ended September 30, 2019 as recommended by the Audit Committee. Copy of the same in the prescribed format in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, along with the Limited Review Report by the Statutory Auditor, is enclosed herewith.
5. Amendment in the Company's Code of Conduct (Prohibition of Insider Trading) for Protection against retaliation and victimization of employees as per amended SEBI (Prohibition of Insider Trading) (Third Amendment) Regulations, 2019 vide notification dated September 17, 2019.





The meeting of Board of Directors of the Company commenced at 11:00 AM and concluded at 1.30 PM.

Please take note of the same.

Thanking you,

Yours sincerely,

For TAKE Solutions Limited



Avaneesh Singh

Company Secretary

Encl: A/a:

November 06, 2019

TAKE/BSE/2019-20

The Manager

Dept. of Corporate Services-Listing

Bombay Stock Exchange Limited,

P. J. Towers, Dalal Street,

Mumbai – 400001

Scrip Code: 532890

TAKE/NSE/2019-20

The Manager-Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra - Kurla Complex, Bandra (East),

Mumbai – 400051

Symbol: TAKE

Dear Sir/Madam,

Sub. : Intimation of Resignation of Independent Director

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, we wish to inform that Mr. G. Raghuram, has step down from the position of the Independent Director of the Company with effect from the close of business hours of November 05, 2019, disclosure with regard to change in Director is given herein under:-

Sr. No	Disclosure Requirement	Details
1.	Reason for resignation	Resignation due to other personal and professional commitments. Mr. G. Raghuram has been associated with the Company since October 15, 2001. Mr. G. Raghuram has expressed his intention to resign as an Independent Director of the Company with effect from the close of business hours of November 05, 2019.
2.	Date of Cessation	November 05, 2019.

Further, the Company has received confirmation from Mr. G. Raghuram that there are no other material reasons for his resignation other than those which are provided in the resignation letter dated November 01, 2019. *The said confirmation received is enclosed herewith.*

Request you to please take the same on your records.

Thanking you,

Yours sincerely,

For TAKE Solutions Limited


Avaneesh Singh
 Company Secretary



Encl: A/a:



प्रोफेसर ग. रघुराम
निदेशक

Professor G. Raghuram
Director

November 01, 2019

The Board of Directors
TAKE Solutions Limited
27, Tank Bund Road
Nungambakkam
Chennai - 600034

Sub.: Confirmation

Dear Sirs,


In connection to my resignation letter dated November 01, 2019, resigning from the position of "Independent Director" of TAKE Solutions Limited with effect from the close of business hours of November 05, 2019 and as per Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("LODR") read with Clause 7B of Part A of Schedule III of LODR, I confirm that there are no other material reasons other than those which I have provided in my resignation letter.

Additional details in connection to my resignation from TAKE Solutions Limited is as below:

Sr. No.	Particulars	Comment
1.	Detailed reasons for the resignation.	Due to other personal and professional commitments, I resign from the position of independent Director of TAKE Solutions Limited.

Thanking You,

Yours Faithfully,


G. Raghuram



Brief Profile – Mr. Balasubramanian Srinivasan (Srini Srinivasan)

Mr. Srinivasan has over 30 years of experience at Pfizer, Novartis, GSK and Astra in global leadership roles in General Management, Commercial, R&D and Manufacturing.



Mr. Srinivasan worked in Europe, USA, Asia Pacific and India. He holds a degree in Pharmacy from Madras Medical College, an MBA from London Business School and received executive training at Harvard Business School.

He delivered business growth and managed P&L as Managing Director in multiple countries and as Head of Asia Pacific region. He drove global growth transformation initiatives including licensing deals, partnering and post-merger integration. He has led organization of over 5,000 associates and developed top talent in different cultures. He is a strong advocate for Diversity & Inclusion. He also managed corporate governance as Chairman of the Board of Directors for a joint venture of Pfizer in India.

Mr. Srinivasan Co-chaired CII National Committee for Pharma in 2018-19. Currently, he is Co-chairman of CII cross industry taskforce on Environment Sustainability and is the Chairman of CII Environment, Health and Safety Excellence Awards. He was an invited speaker at external forums including The Economist Conference, Global Investors Summit, WIPO, Green Chemistry etc. He is an advisor to American Society of Clinical Oncology's Cancer LinQ.



FORM B

**SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(1)(b) read with Regulation 6(2) – Disclosure on becoming a Director]**

Name of the Company: TAKE Solutions Limited

ISIN of the Company: INE142I01023

Details of Securities held by Promoter, Key Managerial Personnel (KMP), Director and other such persons as mentioned in Regulation 6(2)

Name, PAN No., CIN/DIN & address with contact nos.	Category of Person (Promoters/ KMP / Directors/Immediate relatives/others etc)	Date of appointment of Director	Securities held as on the date of regulation coming into force		% of Share holding
			Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No.	
1	2	3	4	5	6
Mr. Balasubramanian Srinivasan PAN: Address: Rainenweg 136 Reinach BL Switzerland 4153	Director	November 06, 2019	Nil	Nil	0.00

Note: "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Details of Open Interest (OI) in derivatives of the company held by Promoter, Key Managerial Personnel (KMP), Director and other such persons as mentioned in Regulation 6(2)

Open Interest of the Future contracts held as on the date of regulation coming into force			Open Interest of the Option Contracts held as on the date of regulation coming into force		
Contract Specifications	Number of units (contracts * lot size)	Notional value in Rupee terms	Contract Specifications	Number of units (contracts * lot size)	Notional value in Rupee terms
7	8	9	10	11	12
Nil	Nil	Nil	Nil	Nil	Nil

Note: In case of Options, notional value shall be calculated based on premium plus strike price of options.

Signature:

Name: Balasubramanian Srinivasan

Designation: Director

Date: 06.11.2019

Place: Chennai

Limited Review Report

The Board of Directors
TAKE Solutions Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of TAKE Solutions Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and half year ended September 30, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the cash flows for the corresponding period from April 1, 2018 to September 30, 2018, as reported in the statement have been approved by the Board of Directors of the company but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the consolidation of results pertaining to the entities listed in Annexure.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matter.

For G. D. Apte & Co.
Chartered Accountants
Firm Registration Number: 100515W
UDIN: 19017532AAAAP7787



C M Dixit
Partner
Membership Number: 017532
Chennai, November 6, 2019



Annexure

Annexure referred to in Paragraph 4 of our Audit Report on the Consolidated Financial Results of TAKE Solutions Limited for the Quarter and half year ended September 30, 2019

Sr. No.	Particulars
A	Subsidiaries
1	APA Engineering Private Limited
2	Ecron Acunova Limited
3	TAKE Solutions Global Holding Pte Ltd.
4	TAKE Solutions Limited ESOP Trust
5	Navitas LLP
B	Step Down Subsidiaries
1	APA Engineering Pte Ltd, Singapore
2	APA Engineering Inc., USA
3	TAKE Solutions Information Systems Pte Ltd, Singapore
4	TAKE Enterprise Services Inc., USA
5	TAKE Innovations Inc, USA
6	Navitas Life Sciences Holdings Limited, UK
7	Million Star Technologies Limited, Mauritius
8	Intelent Inc, USA
9	Navitas Life Sciences Limited, UK
10	Navitas Inc., USA
11	Navitas Life Sciences S.A.S. Colombia
12	Acunova Life Science Inc., USA
13	Navitas Lifesciences Company Limited, Thailand (Formerly known as Ecron Acunova Company Limited)



14	Acunova Life Sciences Limited, UK
15	Navitas Life Sciences, GmbH, Germany
16	Ecron Acunova Sdn. Bhd., Malaysia
17	Ecron Acunova Sp. Z. O. O., Poland
18	Ecron LLC, Ukraine
19	Ecron Acunova LLC, Russia
20	Navitas Life Sciences A/S, Denmark
21	Navitas Life Sciences Pte Ltd, Singapore





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034

www.takesolutions.com

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2019

(₹ In Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Half year Ended		Year Ended
		Sep 30, 2019	Jun 30, 2019	Sep 30, 2018	Sep 30, 2019	Sep 30, 2018	Mar 31, 2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	60,838.13	58,274.30	51,587.95	119,112.43	98,342.03	203,899.85
2	Other Income	650.48	81.81	1,315.13	732.29	2,163.86	1,074.91
3	Total Revenue	61,488.61	58,356.11	52,903.08	119,844.72	100,505.89	204,974.76
4	Expenses						
	Cost of revenue	17,315.86	16,340.82	14,442.09	33,656.68	27,951.16	57,399.66
	Employee benefit expenses	17,500.89	16,205.18	14,896.29	33,706.07	27,967.30	59,162.26
	Finance cost	999.96	1,024.54	555.92	2,024.50	1,079.14	2,501.07
	Depreciation and amortisation	4,049.92	4,501.01	3,921.75	8,550.93	7,227.33	15,350.96
	Other expenses	15,422.21	14,772.83	11,708.90	30,195.04	22,560.13	48,991.88
	Total Expenses	55,288.84	52,844.38	45,524.95	108,133.22	86,785.06	183,405.83
5	Profit/(Loss) before tax (3-4)	6,199.77	5,511.73	7,378.13	11,711.50	13,720.83	21,568.93
6	Tax expense						
	Current tax	1,358.23	957.98	1,014.51	2,316.21	1,961.66	3,199.40
	Shortfall / (excess) provision of earlier years	(21.28)	-	8.07	(21.28)	19.03	27.31
	Deferred tax	(235.24)	(54.71)	276.20	(289.95)	243.94	502.99
7	Profit/(Loss) for the period (5-6)	5,098.06	4,608.46	6,079.35	9,706.52	11,496.20	17,839.23
	Attributable to:						
	Shareholders of the company	5,002.47	4,510.70	6,023.86	9,513.17	11,365.55	17,729.64
	Non-controlling interest	95.59	97.76	55.49	193.35	130.65	109.59
8	Other Comprehensive Income						
	a) i) Items that will not be reclassified to profit or (loss)	(63.30)	(38.33)	5.68	(101.63)	35.51	(42.31)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	(21.25)	(12.53)	(3.74)	(33.78)	5.21	(13.24)
	b) i) Items that will be reclassified to profit or (loss)	(1,958.19)	2,811.17	4,387.49	852.98	8,680.35	3,213.36
	ii) Income tax provision / (reversal) relating to the items that will be reclassified to profit or (loss)	8.24	(8.10)	(48.97)	0.14	(44.16)	17.34
	Total Other Comprehensive Income	(2,008.48)	2,793.47	4,445.88	784.99	8,754.81	3,166.95
	Attributable to:						
	Shareholders of the company	(2,008.78)	2,793.70	4,445.80	784.92	8,754.53	3,167.05
	Non-controlling interest	0.30	(0.23)	0.08	0.07	0.28	(0.10)
9	Total Comprehensive Income	3,089.58	7,401.93	10,525.23	10,491.51	20,251.01	21,006.18
	Attributable to:						
	Shareholders of the company	2,993.69	7,304.40	10,469.66	10,298.09	20,120.08	20,896.69
	Non-controlling interest	95.89	97.53	55.57	193.42	130.93	109.49
10	Paid-up equity share capital (Face value ₹ 1/- each)	1,462.20	1,461.91	1,460.42	1,462.20	1,460.42	1,461.36
11	Earnings per share (of ₹ 1/- each not annualised)						
	(a) Basic	3.42	3.09	4.12	6.51	7.78	12.13
	(b) Diluted	3.42	3.08	4.11	6.50	7.76	12.09

Segment Wise Revenue and Results

Primary Segment Information

Particulars	(₹ In Lakhs)					
	Quarter Ended			Half year Ended		Year Ended
	Sep 30, 2019	Jun 30, 2019	Sep 30, 2018	Sep 30, 2019	Sep 30, 2018	Mar 31, 2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue						
(i) Life Sciences	57,200.55	54,865.06	47,111.55	112,065.61	89,792.07	188,048.57
(ii) Supply Chain Management	3,637.58	3,409.24	4,476.40	7,046.82	8,549.96	15,851.28
Revenue from Operations	60,838.13	58,274.30	51,587.95	119,112.43	98,342.03	203,899.85
2. Segment Results						
(i) Life Sciences	7,737.58	6,883.41	8,623.46	14,620.99	16,391.43	28,457.72
(ii) Supply Chain Management	341.07	363.28	138.49	704.35	250.88	456.48
Total	8,078.65	7,246.69	8,761.95	15,325.34	16,642.31	28,914.20
Less: (i) Finance cost	999.96	1,024.54	555.92	2,024.50	1,079.14	2,501.07
(ii) Other Un-allocable Expenditure net off Un-allocable Income	878.92	710.42	827.90	1,589.34	1,842.34	4,844.20
Profit Before Tax	6,199.77	5,511.73	7,378.13	11,711.50	13,720.83	21,568.93

Segregation of assets, liabilities, depreciation and other non-cash expenses into various primary segments has not been carried out as the assets are used interchangeably between segments. Accordingly, no disclosure relating to segmental assets and liabilities has been made.



Note :		
1. Consolidated Statement of Assets and Liabilities		
(₹ In Lakhs)		
Particulars	As at	As at
	Sep 30, 2019	Mar 31, 2019
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
(a) Property, plant and equipment	29,728.01	26,376.02
(b) Capital work in progress	183.76	141.60
(c) Right-of-use asset	3,677.54	-
(d) Goodwill	22,711.49	23,148.18
(e) Other intangible assets		
(i) Goodwill on business acquisition	30,890.50	30,634.02
(ii) Other intangible assets	28,173.58	28,975.76
(f) Intangible assets under development	4,034.89	3,983.73
(g) Financial Assets		
(i) Investments	670.36	660.92
(ii) Loans	700.45	709.32
(iii) Other financial asset	-	-
(h) Deferred tax assets (net)	619.34	278.99
(i) Income tax assets (net)	957.75	943.89
(j) Other non-current assets	347.77	344.40
Total Non-Current Assets	122,695.44	116,196.84
Current assets		
(a) Inventories	383.79	1,755.40
(b) Financial assets		
(i) Investments	578.31	362.08
(ii) Trade receivables	72,872.08	52,540.41
(iii) Unbilled receivables	15,912.63	17,790.28
(iv) Cash and cash equivalents	7,068.17	4,676.48
(v) Bank balances other than (iii) above	38.28	2,287.34
(vi) Loans	-	216.49
(vii) Other financial assets	18,206.42	20,307.47
(c) Other current assets	17,699.62	17,258.64
Total Current Assets	132,759.30	117,194.59
Total Assets	255,454.74	233,391.43
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,462.20	1,461.36
(b) Other equity	160,039.64	150,361.93
(c) Non-controlling interests	1,088.54	917.71
Total Equity	162,590.38	152,741.00
Non-current liabilities		
(a) Financial liabilities		
Borrowings	19,488.57	3,888.36
(b) Lease liabilities	2,891.66	-
(c) Provisions	672.87	110.74
(d) Deferred tax liabilities (net)	4,284.06	4,269.26
(e) Other non-current liabilities	-	7.64
Total Non-Current Liabilities	27,337.16	8,276.00
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	32,558.40	41,634.05
(ii) Trade Payables	4,368.60	1,427.17
(iii) Other financial liabilities	18,955.99	19,870.97
(b) Lease liabilities	831.62	-
(c) Other current liabilities	5,227.72	5,505.07
(d) Provisions	60.36	447.76
(e) Income tax liabilities (net)	3,524.51	3,489.42
Total Current Liabilities	65,527.20	72,374.43
Total Equity and Liabilities	255,454.74	233,391.43



2. Consolidated Statement of Cash flows

Particulars	(₹ In Lakhs)	
	Six months ended Sep 30, 2019	Six months ended Sep 30, 2018
	(Reviewed)	(Unreviewed)
NET PROFIT/ (LOSS) BEFORE TAX	11,711.50	13,720.83
Adjustments for		
Depreciation and Amortisation	8,550.93	7,227.33
Finance Cost	2,024.50	1,079.14
Interest income	(88.87)	(279.25)
(Profit)/Loss on sale of investments	3.21	(76.53)
Employee stock option expense	135.10	182.67
Dividend income	(0.64)	(73.96)
Provision for Expected credit loss	390.66	(19.72)
Operating Profit before Working Capital Changes	22,726.39	21,760.51
(Increase)/Decrease in loans and adv, trade receivables and other assets	(17,240.97)	(25,644.73)
Increase/ (Decrease) in trade payables, liabilities and provisions	1,910.78	4,631.70
Cash flow from/ (used in) Operations	7,396.20	747.48
Direct taxes paid, net of refunds	(2,273.66)	(324.28)
NET CASH FROM/(USED) IN OPERATING ACTIVITIES	5,122.54	423.20
<u>B) CASH FLOW FROM INVESTING ACTIVITIES</u>		
Purchase of Property Plant and Equipment and Intangible Assets & Sale of Property Plant and Equipment	(10,955.47)	(4,237.17)
(Purchase) /Sale of investments	(214.76)	235.19
Dividend income	0.64	73.96
Interest income	88.87	279.25
Reduction/ (Increase) of bank deposits	2,249.02	86.51
NET CASH FROM/(USED) IN INVESTING ACTIVITIES	(8,831.70)	(3,562.26)
<u>C) CASH FLOW FROM FINANCING ACTIVITIES</u>		
Net movement in Long/short-term borrowings	9,249.10	1,837.47
Proceeds from exercise of employee options	61.47	115.37
Dividend Paid on equity shares including dividend distribution tax	(706.50)	(1,766.50)
Payment of Lease Liability	(732.56)	-
Finance Cost	(1,823.10)	(1,079.14)
NET CASH FROM/(USED) IN FINANCING ACTIVITIES	6,048.41	(892.80)
Net Increase/(Decrease) in Cash & Cash equivalents	2,339.25	(4,031.86)
Add: Cash and cash equivalents as at the beginning of the period	4,676.50	31,713.90
Exchange difference on translation of foreign currency cash and cash equivalents	52.42	2,916.50
Cash & Cash equivalents as at the end of the period	7,068.17	30,598.54

- The Consolidated Financial Results for the quarter and half year ended September 30, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on November 06, 2019. The statutory auditors of the company have carried out Limited Review of the results for the quarter and half year ended September 30, 2019.
- Effective April 1, 2019, the Group adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to September 30, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right -of-use asset and corresponding lease liability. Accordingly, comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- The Consolidated and Standalone financial results for the quarter and half year ended September 30, 2019 are available on the Company's website (www.takesolutions.com) and the website of BSE (www.bseindia.com) and NSE (www.nseindia.com)
- During the quarter ended September 30, 2019, employees exercised 29,200 equity shares under Employee Stock Option Scheme of the Group.
- The financial results of TAKE Solutions Limited (Standalone information)

(₹ In Lakhs)

Particulars	Quarter Ended			Half year Ended		Year Ended
	Sep 30, 2019	Jun 30, 2019	Sep 30, 2018	Sep 30, 2019	Sep 30, 2018	Mar 31, 2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	1,201.78	638.75	3,453.55	1,840.53	6,130.49	5,630.74
Net profit/(loss) before tax	545.76	148.03	2,949.85	693.79	5,289.86	1,950.83
Net profit/(loss) for the period	608.72	158.19	2,738.48	766.91	4,954.52	1,739.47
Total comprehensive income	608.08	157.42	2,732.95	765.50	4,956.41	1,736.39

- Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

For and on behalf of the Board of Directors


 Srinivasan H.R.
 Vice Chairman & Managing Director



Place : Chennai
Date : November 06, 2019



Limited Review Report

The Board of Directors
TAKE Solutions Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of TAKE Solutions Limited for the quarter and half year ended September 30, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. Attention is drawn to the fact that the cash flows for the corresponding period from April 1, 2018 to September 30, 2018, as reported in the statement have been approved by the Board of Directors of the company but have not been subjected to review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. D. Apte & Co.
Chartered Accountants
Firm Registration Number: 100515W
UDIN: 19017532AAAAAO5814



C. M. Dixit
Partner
Membership Number: 017532
Chennai, November 6, 2019





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034

www.takesolutions.com

Statement of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2019

(₹ In Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sep 30, 2019	Jun 30, 2019	Sep 30, 2018	Sep 30, 2019	Sep 30, 2018	Mar 31, 2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	91.28	48.46	24.66	139.74	64.85	2,195.86
2	Other Income	1,110.50	590.29	3,428.89	1,700.79	6,065.64	3,434.88
3	Total Income	1,201.78	638.75	3,453.55	1,840.53	6,130.49	5,630.74
4	Expenses						
	Cost of revenue	52.62	21.80	24.49	74.42	58.07	1,815.66
	Employee benefit expenses	166.37	186.00	169.54	352.37	291.08	682.19
	Finance cost	11.02	11.30	-	22.32	-	-
	Depreciation and amortisation	45.02	45.52	20.11	90.54	40.28	80.18
	Other expenses	380.99	226.10	289.56	607.09	451.20	1,101.88
	Total Expenses	656.02	490.72	503.70	1,146.74	840.63	3,679.91
5	Profit/(Loss) before tax (3-4)	545.76	148.03	2,949.85	693.79	5,289.86	1,950.83
6	Tax expense						
	Current tax	7.10	22.68	206.63	29.78	371.95	230.19
	Deferred tax	(70.06)	(32.84)	4.74	(102.90)	(36.61)	(18.83)
7	Profit/(Loss) for the period (5-6)	608.72	158.19	2,738.48	766.91	4,954.52	1,739.47
8	Other Comprehensive Income						
	a) i) Items that will not be reclassified to profit or (loss)	(0.90)	(1.08)	(7.66)	(1.98)	2.61	(4.27)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	(0.26)	(0.31)	(2.13)	(0.57)	0.72	(1.19)
	b) i) Items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	ii) Income tax provision/(reversal) relating to the items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	Total Other Comprehensive Income	(0.64)	(0.77)	(5.53)	(1.41)	1.89	(3.08)
9	Total Comprehensive Income	608.08	157.42	2,732.95	765.50	4,956.41	1,736.39
10	Paid-up equity share capital (Face value ₹ 1/- each)	1,479.34	1,479.34	1,479.34	1,479.34	1,479.34	1,479.34
11	Earnings per share (of ₹ 1/- each) (not annualised)						
	(a) Basic (in ₹)	0.41	0.11	1.85	0.52	3.35	1.18
	(b) Diluted (in ₹)	0.41	0.11	1.84	0.52	3.33	1.17



Note:

1. Standalone Statement of Assets and Liabilities

		(₹ In Lakhs)	
Particulars		As at Sep 30, 2019	As at Mar 31, 2019
		(Unaudited)	(Audited)
ASSETS			
Non-current assets			
(a)	Property, plant and equipment	268.63	305.38
(b)	Right-of-use assets	412.26	-
(c)	Other intangible assets	-	1.65
(d)	Investment in subsidiaries	51,599.90	51,171.52
(e)	Financial Assets		
	(i) Loans	615.00	658.05
	(ii) Other financial asset	-	-
(f)	Deferred tax assets (net)	261.37	157.90
(g)	Income tax assets (net)	834.15	808.11
(h)	Other non-current assets	-	-
	Total Non-Current Assets	53,991.31	53,102.61
Current assets			
(a)	Inventories	1.58	3.23
(b)	Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	682.09	643.13
	(iii) Cash and cash equivalents	1,127.89	212.16
	(iv) Bank balances other than (iii) above	32.08	2,281.14
	(v) Loans	12,313.86	11,494.98
	(vi) Other financial assets	8,859.69	9,426.79
(c)	Other current assets	509.45	262.23
	Total Current Assets	23,526.64	24,323.66
	Total Assets	77,517.95	77,426.27
EQUITY AND LIABILITIES			
Equity			
(a)	Equity share capital	1,479.34	1,479.34
(b)	Other equity	74,921.21	74,765.86
	Total Equity	76,400.55	76,245.20
Non-current liabilities			
(a)	Financial liabilities		
	Other financial liabilities	256.12	65.53
(b)	Lease liabilities	353.24	-
(c)	Provisions	83.66	77.32
	Total Non-Current Liabilities	693.02	142.85
Current liabilities			
(a)	Financial liabilities		
	(i) Trade Payables	104.07	40.53
	(ii) Other financial liabilities	226.37	977.86
(b)	Lease liabilities	66.50	-
(c)	Other current liabilities	20.95	13.41
(d)	Provisions	6.49	6.42
	Total Current Liabilities	424.38	1,038.22
	Total Equity and Liabilities	77,517.95	77,426.27



2. Standalone Statement of Cash flows

Particulars	₹ In Lakhs	
	Six months ended Sep 30, 2019	Six months ended Sep 30, 2018
	(Unaudited)	(Unreviewed)
A) CASH FLOW FROM OPERATING ACTIVITIES		
NET PROFIT/ (LOSS) BEFORE TAX	693.79	5,289.86
Adjustments for		
Depreciation	90.54	40.28
Finance Cost	22.32	-
Dividend income	(24.86)	(98.23)
Interest income	(469.85)	(668.23)
Provision for gratuity, compensated absences & other benefits	5.26	(5.89)
Employee stock option expense	71.12	95.66
Bad debts and provision for expected credit losses	15.59	22.14
Foreign exchange adjustments - loss/(gain)	69.29	(666.20)
(Gain)/Loss on Fair Valuation/Redemption of Mutual Funds	-	(147.82)
Operating Profit before working Capital Changes	473.20	3,861.57
(Increase)/Decrease in loans & advances and other assets	(483.10)	(5,353.69)
Increase/ (Decrease) in liabilities and provisions	(516.11)	(428.64)
Cash flow from/ (used in) Operations	(526.01)	(1,920.76)
Direct taxes paid	(55.83)	151.48
NET CASH FROM/(USED IN) OPERATING ACTIVITIES	(581.84)	(1,769.28)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	-	(0.60)
Sale/(Purchase) of investments	-	367.53
Dividend income	24.86	98.23
Interest income	469.85	668.23
Loans to related parties	(773.91)	(10,326.65)
Reduction/ (Increase) of bank deposits	2,545.50	-
NET CASH FROM / (USED IN) INVESTING ACTIVITIES	2,266.30	(9,193.26)
C) CASH FLOW FROM FINANCING ACTIVITIES		
Payment of lease liabilities	(60.46)	-
Dividends paid on equity share including dividend distribution tax	(708.30)	(1,780.50)
NET CASH FROM/(USED IN) FINANCING ACTIVITIES	(768.76)	(1,780.50)
Net Increase/(Decrease) in Cash & Cash equivalents	915.70	(12,743.04)
Add: Cash and Cash equivalents as at the beginning of the period	212.19	12,956.55
Cash & Cash equivalents as at the end of the period	1,127.89	213.51

- The Standalone Financial Results for the quarter and half year ended September 30, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on November 06, 2019. The statutory auditors of the company have carried out Limited Review of the results for the quarter and half ended September 30, 2019.
- Effective April 1, 2019, the Company adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to September 30, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right-of-use asset and corresponding lease liability. Accordingly, comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- During the quarter ended September 30, 2019, employees exercised 29,200 equity shares under Employee Stock Option Scheme of the Group.
- Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

For and on behalf of the Board of Directors

Srinivasan H.R.

Srinivasan H.R.
Vice Chairman & Managing Director

Place : Chennai

Date : November 06, 2019

